Physicians

Department / Division
Pediatrics / Pediatrics-Infectious Diseases

Address
DUMC 3461
Durham, NC 27710

Appointment Telephone
919-684-6335

Office Telephone
919-668-9000

Fax Telephone
919-668-5239

Training

• MD, University of Rochester School of Medicine and Dentistry (New York), 1979

Residency

• Pediatrics, Duke University Medical Center, 1979-1982

Fellowship

• Pediatric Infectious Diseases, Duke University Medical Center, 1982-1985

Clinical Interests
Pediatric HIV infection and AIDS, evaluation of recurrent infections, evaluation of fevers of unknown origin (FUO)

Research Interests
RESEARCH ABSTRACT

Dr. Ross McKinney's research is in the antiretroviral treatment of HIV infected children.  In addition, he has published articles on the natural history and pathogenesis of pediatric HIV disease.  Dr. McKinney chaired Pediatric AIDS Clinical Trials Group Protocol 300, a large (600 patient) study of zidovudine, didanosine, and lamivudine in HIV infected children. He recently Co-chaired PACTG 1021 (A phase I-II study of FTC, DDI, and efavirenz), and PACTG 390/PenPact 1 (an international study of treatment strategies for therapy naive children). Dr. McKinney also cochaired PACTG 247, a study of nutritional supplementation in HIV exposed and infected infants.

As of July 2007, Dr. McKinney became the director of the Trent Center for Bioethics, Humanities, and History of Medicine in the Duke University School of Medicine.  His current research involves the ethics of medical research, with a particular focus on conflict of interest and on the informed consent process.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Applied Genetic Technologies Corporation
• Gilead Sciences, Inc.

Representative Publications
PenPact1 (PENTA 9/PACTG 390) Study Team. First-line antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor combination and switch at higher versus low viral load in HIV-infected children: an open-label randomised controlled phase 2/3 trial. Lancet Infectious Diseases 2011;11:273-283 [Study Co-chair] PMID: 21288774 (2011)

McKinney R, Abernethy AP, Matchar DB, Wheeler JL. White Paper: Potential conflict of interest in the production of drug compendia.  CMS Technology Assessment Web Site: [http://www.cms.hhs.gov/determinationprocess/downloads/id64TA.pdf – accessed 6/9/09] (2009)

Weinberg A, Dickover R, Britto P, Hu C, Patterson-Bartlett J, Kraimer J, Gutzman H, Shearer W, Rathore M, McKinney R, PACTG 1021 Team. Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS 2008;22:2267-2277 (2008)

McKinney RE Jr, Cunningham CK. Newer treatments for HIV in children. Curr Opin Pediatr. 2004 Feb;16(1):76-9. (2004) Abstract

Benjamin Jr DK, Miller WC, Benjamin DK, Ryder RW, Weber DJ, Walter E, McKinney RE. A comparison of height and weight velocity as a part of the composite endpoint in pediatric HIV.  AIDS.  2003 Nov 7;17(16):2331-2336. (2003) Abstract

HIV Paediatric Prognostic Markers Collaborative Study Group (R. McKinney - Steering Committee Member); Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy:a meta-analysis. Lancet 2003;362:1605-1611 (2003)

McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team. J Pediatr. 1998 Oct;133(4):500-8. (1998) Abstract

Fiscus SA, Adimora AA, Schoenbach VJ, Lim Wilma, McKinney R, Rupar D, Kenny J, Woods C, Wilfert C. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996;275:1483-1488 (1996)

McKinney RE Jr, Wilfert C. Growth as a prognostic indicator in children with human immunodeficiency virus infection treated with zidovudine. AIDS Clinical Trials Group Protocol 043 Study Group. J Pediatr. 1994 Nov;125(5 Pt 1):728-33. (1994) Abstract

McKinney RE Jr, Maha MA, Connor EM, Feinberg J, Scott GB, Wulfsohn M, McIntosh K, Borkowsky W, Modlin JF, Weintrub P. A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group. N Engl J Med. 1991 Apr 11;324(15):1018-25. (1991) Abstract

McKinney RE Jr, Pizzo PA, Scott GB, Parks WP, Maha MA, Lehrman SN, Riggs M, Eddy J, Lane BA, Eppes SC. Safety and tolerance of intermittent intravenous and oral zidovudine therapy in human immunodeficiency virus-infected pediatric patients. Pediatric Zidovudine Phase I Study Group. J Pediatr. 1990 Apr;116(4):640-7. (1990) Abstract

Balis FM, Pizzo PA, Wilfert CM, Scott G, McKinney R, Eddy J, Murphy RF, Jarosinski BS, Falloon J, Poplack DG.  The pharmacokinetics of Azidothymidine administered intravenously and orally on an intermittent schedule in children with HIV infection. J Pediatr 1989; 114:880-884 (1989)